Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingPE,epsTrailingTwelveMonths,epsForward,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GNMSF,19778000000,65339700,848000000,,1424000000,,1096000000,201000000,1581000000,532000000,532000000,,-3000000,,,,328000000,1581000000,1049000000,0,892000000,,1096000000,1096000000,317000000,11914000000,2115000000,20095000000,1241000000,22210000000,66000000,8020000000,496000000,95000000,209000000,7892000000,1293000000,177000000,95000000,842000000,19937000000,905000000,10191000000,1854000000,-551000000.0,0.0,-579000000.0,-12000000.0,-220000000.0,500000000.0,20000000.0,632000000.0,-228000000.0,246000000.0,1185000000.0,11000000.0,-422000000.0,-28000000.0,,18644000000,en-US,US,EQUITY,False,Delayed Quote,482.89,1630525884,5.3200073,483.35,483.35,470.08,160,86.06668,0.21688916,32541186048,67.254875,1.5712069,15,America/New_York,EDT,-14400000,False,False,USD,2,GENMAB AS,PNK,35.91,13.447229,307.337,456.68344,26.206573,0.05738455,396.82333,0,finmb_665704,Other OTC,Genmab A/S,DKK,525,157,183.81003,0.61458486,299.08 - 490.07,-7.1799927,-0.014650953,299.08,490.07,35.519676,13.595,7.18,PREPRE,1.1139743,470.08 - 483.35,477.57,0.0,0.0,0,0,us_market,0.59,,,490.07,299.08,456.68,396.82,525,157,65.34M,,64.67M,4.63%,51.84%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",51.71%,62.93%,22.65%,32.38%,10.8B,165.53,77.20%,10.11B,7.05B,5.58B,13.60,307.40%,18.08B,276.57,378M,1.88,15.42,307.34,5.7B,4.25B,Value,1560,Healthcare,871,6,2,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 20 27 28,1,1609372800,1622505600,1,Denmark,http://www.genmab.com,86400,1,Kalvebod Brygge 43,Biotechnology
t-1,GNMSF,18783000000,65339700,904000000,,551000000,,581000000,231000000,2044000000,909000000,909000000,,-3000000,,,,-30000000,2044000000,1135000000,0,-358000000,,581000000,581000000,338000000,11894000000,2022000000,19121000000,1211000000,21143000000,66000000,7107000000,492000000,54000000,197000000,7260000000,1253000000,177000000,54000000,736000000,18791000000,1081000000,8819000000,2712000000,-656000000.0,681000000.0,-714000000.0,-14000000.0,33000000.0,-1487000000.0,53000000.0,-1632000000.0,-6000000.0,-153000000.0,-798000000.0,241000000.0,-1120000000.0,-58000000.0,306000000.0,17538000000,en-US,US,EQUITY,False,Delayed Quote,482.89,1630525884,5.3200073,483.35,483.35,470.08,160,86.06668,0.21688916,32541186048,67.254875,1.5712069,15,America/New_York,EDT,-14400000,False,False,USD,2,GENMAB AS,PNK,35.91,13.447229,307.337,456.68344,26.206573,0.05738455,396.82333,0,finmb_665704,Other OTC,Genmab A/S,DKK,525,157,183.81003,0.61458486,299.08 - 490.07,-7.1799927,-0.014650953,299.08,490.07,35.519676,13.595,7.18,PREPRE,1.1139743,470.08 - 483.35,477.57,0.0,0.0,0,0,us_market,0.59,,,490.07,299.08,456.68,396.82,525,157,65.34M,,64.67M,4.63%,51.84%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",51.71%,62.93%,22.65%,32.38%,10.8B,165.53,77.20%,10.11B,7.05B,5.58B,13.60,307.40%,18.08B,276.57,378M,1.88,15.42,307.34,5.7B,4.25B,Value,1560,Healthcare,871,6,2,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 20 27 28,1,1609372800,1622505600,1,Denmark,http://www.genmab.com,86400,1,Kalvebod Brygge 43,Biotechnology
t-2,GNMSF,18092000000,65339700,721000000,,671000000,,530000000,145000000,1724000000,858000000,858000000,,-720000000,,,,141000000,1724000000,866000000,0,-187000000,,530000000,530000000,385000000,11875000000,3045000000,18477000000,2216000000,21522000000,65000000,6463000000,492000000,74000000,256000000,8892000000,2258000000,236000000,74000000,730000000,19504000000,647000000,8577000000,2035000000,-2519000000.0,0.0,-2565000000.0,-13000000.0,19000000.0,4057000000.0,33000000.0,2287000000.0,-1000000.0,-245000000.0,5078000000.0,10000000.0,481000000.0,-46000000.0,306000000.0,17246000000,en-US,US,EQUITY,False,Delayed Quote,482.89,1630525884,5.3200073,483.35,483.35,470.08,160,86.06668,0.21688916,32541186048,67.254875,1.5712069,15,America/New_York,EDT,-14400000,False,False,USD,2,GENMAB AS,PNK,35.91,13.447229,307.337,456.68344,26.206573,0.05738455,396.82333,0,finmb_665704,Other OTC,Genmab A/S,DKK,525,157,183.81003,0.61458486,299.08 - 490.07,-7.1799927,-0.014650953,299.08,490.07,35.519676,13.595,7.18,PREPRE,1.1139743,470.08 - 483.35,477.57,0.0,0.0,0,0,us_market,0.59,,,490.07,299.08,456.68,396.82,525,157,65.34M,,64.67M,4.63%,51.84%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",51.71%,62.93%,22.65%,32.38%,10.8B,165.53,77.20%,10.11B,7.05B,5.58B,13.60,307.40%,18.08B,276.57,378M,1.88,15.42,307.34,5.7B,4.25B,Value,1560,Healthcare,871,6,2,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 20 27 28,1,1609372800,1622505600,1,Denmark,http://www.genmab.com,86400,1,Kalvebod Brygge 43,Biotechnology
t-3,GNMSF,17458000000,65339700,775000000,,4328000000,,3378000000,179000000,5451000000,4497000000,4497000000,,-211000000,,,,950000000,5451000000,954000000,0,-169000000,,3378000000,3378000000,413000000,11826000000,2812000000,17871000000,1966000000,20683000000,65000000,5882000000,490000000,98000000,251000000,6605000000,2009000000,239000000,98000000,726000000,19141000000,152000000,6177000000,6359000000,1064000000.0,0.0,919000000.0,-9000000.0,4000000.0,-4672000000.0,17000000.0,784000000.0,-4000000.0,-100000000.0,-39000000.0,8000000.0,1247000000.0,-145000000.0,306000000.0,17132000000,en-US,US,EQUITY,False,Delayed Quote,482.89,1630525884,5.3200073,483.35,483.35,470.08,160,86.06668,0.21688916,32541186048,67.254875,1.5712069,15,America/New_York,EDT,-14400000,False,False,USD,2,GENMAB AS,PNK,35.91,13.447229,307.337,456.68344,26.206573,0.05738455,396.82333,0,finmb_665704,Other OTC,Genmab A/S,DKK,525,157,183.81003,0.61458486,299.08 - 490.07,-7.1799927,-0.014650953,299.08,490.07,35.519676,13.595,7.18,PREPRE,1.1139743,470.08 - 483.35,477.57,0.0,0.0,0,0,us_market,0.59,,,490.07,299.08,456.68,396.82,525,157,65.34M,,64.67M,4.63%,51.84%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",51.71%,62.93%,22.65%,32.38%,10.8B,165.53,77.20%,10.11B,7.05B,5.58B,13.60,307.40%,18.08B,276.57,378M,1.88,15.42,307.34,5.7B,4.25B,Value,1560,Healthcare,871,6,2,"Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 20 27 28,1,1609372800,1622505600,1,Denmark,http://www.genmab.com,86400,1,Kalvebod Brygge 43,Biotechnology
